

January 27, 2014

In accordance with Section 28a of the Danish Securities Trading Act, Novozymes reports the following transactions under ISIN DK0060336014, Novozymes B shares under the symbol NZYM B.

Name	Novo A/S	
Relation/category of close relation	Novo A/S is closely related to the chairman of	
	Novozymes' board of directors, Henrik Gürtler	
Trading date	January 24, 2014	
Market	Nasdaq OMX Copenhagen A/S	
Character of transaction	Sale of shares	
Volume of transaction buy(+)/ sell (-)	-80,000	
Value of transaction (DKK)	18,706,504.00 DKK	

This sale has been completed according to earlier communicated intention by Novo A/S to keep its relative holding of Novozymes B shares at the level it held prior to Novozymes' cancellation of B shares on 5 April 2013 (Company announcement no. 50, August, 2011).

Name	Thomas Videbæk	
Relation/category of close relation	EVP, Business Development	
Trading date	January 24, 2014	
Market	Nasdaq OMX Copenhagen A/S	
Character of transaction	Sale of shares	
Volume of transaction buy(+)/ sell (-)	-37,059	
Value of transaction (DKK)	8,656,984.25 DKK	



Contact information

Investor Relations:

Thomas Bomhoff (DK)	+45 3077 1226	tsbm@novozymes.com
Klaus Sindahl (DK)	+45 5363 0134	ksdh@novozymes.com
Martin Riise (USA)	+1 919 649 2565	mrsn@novozymes.com
Press and media:		
Rene Tronborg (DK)	+45 3077 2274	retr@novozymes.com
Frederik Bjoerndal (Europe)	+45 3077 0236	tfbh@novozymes.com
Paige Donnelly (USA)	+1 919 218 4501	pagd@novozymes.com
Meng Lian (China)	+86 136 9923 1164	mexl@novozymes.com
Henrique Pellini (Brazil)	+55 41 9288 0282	hqp@novozymes.com
Poonam Kapila (India)	+91 991 082 2339	poka@novozymes.com

Novozymes is the world leader in bioinnovation. Together with customers across a broad array of industries we create tomorrow's industrial biosolutions, improving our customers' business and the use of our planet's resources. Read more at www.novozymes.com.